Brainstorm Cell Therapeutics (NASDAQ:BCLI) issued its earnings results on Thursday. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.26) by $0.12, MarketWatch Earnings reports.
Brainstorm Cell Therapeutics stock opened at $13.86 on Friday. The stock has a market cap of $437.53 million, a P/E ratio of -11.95 and a beta of 0.83. Brainstorm Cell Therapeutics has a twelve month low of $3.58 and a twelve month high of $17.95. The company’s 50-day moving average price is $14.66 and its two-hundred day moving average price is $10.71.
BCLI has been the subject of several recent analyst reports. Maxim Group raised their target price on shares of Brainstorm Cell Therapeutics from $9.00 to $20.00 and gave the company a “buy” rating in a research note on Wednesday, July 8th. BidaskClub downgraded shares of Brainstorm Cell Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Saturday.
Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of central nervous system (CNS) adult stem cell therapies designed to address the unmet medical needs of patients with debilitating neurodegenerative diseases. The company holds rights to develop and commercialize its NurOwn technology that utilizes a patient's own cells, which are engineered outside the body, to produce and secrete factors known to promote neuronal survival.
Recommended Story: How to calculate compound interest
Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.